Ionis Pharmaceuticals Surges After-Hours on FDA Priority Review for Hepatitis B Drug
Ionis Pharmaceuticals Inc. (IONS) shares jumped 4.08% in after-hours trading Tuesday following news that the U.S. Food and Drug Administration (FDA) has granted Priority Review and Breakthrough Therapy designation to bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. The move sharply outperformed the broader market, with the S&P 500 remaining flat in extended session activity.
FDA Fast-Tracks Potential Hepatitis B 'Functional Cure'
Ionis Pharmaceuticals (IONS) saw a significant spike in extended trading after the company and its partner, GSK, announced that the FDA accepted the New Drug Application (NDA) for bepirovirsen with a Priority Review status. This designation shortens the regulatory review period, with the FDA setting a Prescription Drug User Fee Act (PDUFA) action date for October 26, 2026.
In addition to the expedited review, the FDA granted bepirovirsen Breakthrough Therapy designation. This status is reserved for medicines intended to treat serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies. Bepirovirsen is an investigational antisense oligonucleotide designed to reduce the replication of the hepatitis B virus and stimulate the immune system, aiming for what researchers call a "functional cure"—a state where the virus is undetectable in the blood without the need for lifelong medication.
Strategic Partnership and Financial Impact
The move is a major validation of Ionis’ RNA-targeted technology platform. Under the terms of the 2019 licensing agreement with GSK, Ionis has already received upfront and milestone payments and remains eligible for further regulatory and sales milestones. Crucially for long-term investors, Ionis is entitled to tiered royalties of 10% to 12% on net global sales if the drug reaches the market.
Chronic hepatitis B (CHB) represents a massive global health challenge, affecting approximately 250 million people worldwide and 1.7 million in the United States. Current standards of care typically require lifelong antiviral therapy and offer functional cure rates of only about 1%. Bepirovirsen’s potential to disrupt this landscape has made it a cornerstone of Ionis’ late-stage pipeline.
Market Context and Upcoming Earnings
The 4.08% after-hours surge to a volume of 2.4 million shares comes at a critical time for the biotech firm. Ionis is scheduled to report its first-quarter 2026 financial results tomorrow morning, April 29, before the market opens. Analysts are currently forecasting a loss of $0.85 to $0.88 per share on revenue of approximately $197 million.
Wall Street remains overwhelmingly bullish on the stock ahead of these milestones. The consensus rating for IONS is a "Strong Buy," with recent price target hikes from major firms including Morgan Stanley ($130) and Canaccord Genuity ($110). Analysts have pointed to the company's transition toward a commercial-stage powerhouse, with multiple independent launches like olezarsen and zilganersen also expected in 2026. Today's regulatory win provides a tailwind for the stock as it heads into a high-stakes earnings call.
Key Takeaways
- Ionis shares rose 4.08% after-hours following FDA Priority Review and Breakthrough Therapy designation for its hepatitis B drug, bepirovirsen.
- The FDA has set a PDUFA target action date of October 26, 2026, for the potential first-in-class treatment.
- The move comes just hours before Ionis is set to report Q1 2026 financial results on the morning of April 29.
- Ionis is eligible for 10-12% royalties on net sales from partner GSK, targeting a global market of 250 million chronic hepatitis B patients.